甲氨蝶呤用于异位妊娠高风险不明位置妊娠女性的安全性
该回顾性观察研究纳入2007至2021年悉尼Nepean医院早期妊娠单元816例不明位置妊娠(PUL)女性,将ACOG、ASRM、RCOG、NICE指南标准应用于数据库。结果显示各指南下MTX使用率分别为2.76%、4.56%、0.41%、35.36%,ACOG与ASRM标准理论上可致4.1/1000(3/724)例潜在存活宫内妊娠误用MTX。
要点
- ACOG与ASRM指南标准下MTX使用率分别为2.76%与4.56%,理论上可致存活宫内妊娠误用MTX 4.1/1000(3/724)。
- NICE指南标准下MTX使用率最高达35.36%,多数MTX治疗不必要,患者后续被归类为非存活宫内妊娠或失败PUL。
- ACOG、ASRM与RCOG方案下无持续PUL接受MTX,NICE方案识别持续PUL的敏感度为100%。
核心结论
- 现行用于预测PUL人群中异位妊娠高风险的指南可导致潜在存活宫内妊娠女性误用MTX,应审慎使用以确保无意愿妊娠暴露于MTX,PUL女性应仔细监测,妊娠位置未确认时MTX应审慎使用。
研究设计与样本
- 回顾性观察研究,纳入2007至2021年澳大利亚悉尼Nepean医院早期妊娠单元连续临床稳定的PUL女性816例,其中724例数据完整纳入最终分析;PUL定义为经阴道超声未见宫内妊娠或异位妊娠征象而妊娠试验阳性;将ACOG、ASRM、RCOG与NICE指南标准应用于PUL数据库。
诊断标准与关键数值
- ACOG指南标准下MTX使用率为2.76%,ASRM为4.56%,RCOG为0.41%,NICE为35.36%;NICE方案识别持续PUL的敏感度为100%;ACOG与ASRM标准理论上可致存活宫内妊娠误用MTX的发生率为4.1/1000(3/724)。
临床应用与阅片要点
- 作者认为现行指南应审慎使用以确保无意愿妊娠暴露于MTX,PUL女性应仔细监测,妊娠位置未确认时MTX应审慎使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the safety of current guidelines on methotrexate (MTX) administration in women with pregnancy of unknown location (PUL) who are considered to have a high risk of underlying ectopic pregnancy (EP), and to investigate whether implementation of these guidelines would result in inadvertent exposure to MTX of viable intrauterine pregnancies (IUPs).
METHODS: This was a retrospective observational study of consecutive clinically stable women who were classified with PUL at the early pregnancy unit of Nepean Hospital, Sydney, Australia, between 2007 and 2021. PUL was defined as a positive pregnancy test in the absence of signs of IUP or EP on transvaginal ultrasound. Patients with a PUL that behaved biochemically like an EP, but for which the location of pregnancy was not confirmed on ultrasound, were eligible for MTX to minimize the risk of subsequent tubal rupture. Criteria discussed in the guidelines of the American College of Obstetricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ASRM), Royal College of Obstetricians and Gynaecologists (RCOG) and National Institute for Health and Care Excellence (NICE) were applied to the PUL database. The number of patients eligible to receive MTX and the number with an underlying viable IUP who would be inadvertently prescribed MTX were calculated.
RESULTS: A total of 816 women with PUL were reviewed, of whom 724 had complete data and were included in the final analysis. Six patients had persistent PUL and the remaining 718 had a diagnosis of viable IUP, non-viable IUP, EP or failed PUL. According to the ACOG, ASRM, RCOG and NICE guidelines, the rate of MTX administration among patients with PUL would have been 2.76%, 4.56%, 0.41% and 35.36%, respectively. However, no persistent PUL would have received MTX according to the ACOG, ASRM and RCOG protocols (the NICE protocol identified patients with persistent PUL with a sensitivity of 100%), and the majority of MTX treatments were unnecessary because those patients were later classified as having non-viable IUP or failed PUL. Application of ACOG and ASRM guidance could result theoretically in inadvertent MTX administration to women with an underlying viable IUP at a rate of 4.1/1000 (3/724).
CONCLUSIONS: Current guidelines used to predict high risk of EP in the PUL population lead to inadvertent MTX administration to women with an underlying viable IUP. These guidelines should be used wisely to ensure that no wanted pregnancy is exposed to MTX. Women with PUL should be monitored carefully, and MTX should be used judiciously when the location of pregnancy is yet to be confirmed. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Jin CS, Uzuner C, Condous G, et al. Safety of methotrexate administration in women with pregnancy of unknown location at high risk of ectopic pregnancy. Ultrasound Obstet Gynecol. 2024. PMID: 38279942. doi:10.1002/uog.27593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。